– New Step Forward in Ophthalmology with Cell Therapy Approach –   TOKYO and MASSACHUSETTS, Nov. 9, 2015 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas“) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, “Ocata“), a biotechnology company focused on the research and development of new therapies in […]

Drug developer Avalanche Biotechnologies Inc said it would not start a second mid-stage study of its eye drug, which showed only a modest improvement in vision in the first study. Avalanche’s shares fell 15 percent in extended trading on Thursday after closing at $13.83. The drug developer said it was stepping back from clinical trials […]

Regeneron Inc’s blockbuster eye drug, Eylea, showed no signs of a slowdown as the drugmaker raised the full-year sales forecast for its flagship product above at least four analysts’ expectation. The company’s shares rose to a record of $605.93 in early trading on Tuesday. U.S. sales of Eylea surged 58 percent to $655 million in […]